Sector: plasma derivatives
Kedrion is a leading Italian operator and in 5th place worldwide in the sector of plasma derivatives, pharmaceuticals developed from proteins extracted from human plasma and used to cure coagulation disorders, infectious diseases, primary immunodeficiency disorders and neuropathologies, and in other areas of treatment.
Cdp Equity investment and objective
Project for the creation of a leading operator in the sector via growth abroad, both systematic and via acquisitions.
Cdp Equity’s investment has made it possible to acquire an American division of the Johnson&Johnson group active in the production of the medicine under the RhoGAM® brand.